
    
      Primary Objective: To evaluate the pharmacokinetics of lipo-PGE1. Secondary objective: To
      evaluate the relation between lipo-PGE1 concentration and VOD occurrence, severity.

      Inclusion criteria

        1. Patients undergoing HSCT with high risk of VOD who cannot use low dose heparin.

             -  high risk of VOD : previous radiotherapy, liver function abnormality, children,
                conditioning regimen including busulfan or total body irradiation

             -  contraindication of heparin : low platelet count, bleeding tendency, allergy

        2. Patients (or one of parents if patients age < 19) should sign informed consent.

      Exclusion criteria

        1. Patient with heart failure.

        2. Patient with bleeding (intracranial hemorrhage, gastrointestinal tract bleeding,
           hemoptysis).

        3. History of hypersensitivity reaction as shock to lipo-PGE1.

        4. Psychiatric disorder that would preclude compliance.

        5. If the clinician decides that there is a condition improper for the clinical study.
    
  